Committed to Improving Patients’ Life
Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
Innovative Medicines for Healthy Life.
To Become the Leading Company Driving Global Innovation of NextGen Antibody Therapeutics.
HBM’s efforts are driven by our vision of delivering “Innovative Medicines for Healthy Life”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.
Our strategic priorities are focused on driving global inventions of transformative next generation medicines powered by our proprietary technology platforms and data driven science.
Immunotherapies have been increasingly recognized as critical components of evolving treatment paradigms owing to the superior efficacy and safety profiles. However, the current standards of care in oncology and immunological diseases fall short owing to complexities of these multicomponent, multifactorial diseases, thereby limiting the response and outcomes in most patient populations.
With a strong patient-centric approach, we combine the power of Harbour Mice® with other advanced technologies, like single B cell cloning, bispecific antibody, bioinformatics and translational research to generate and identify lead antibody candidates to treat diseases. Our highly efficient antibody discovery engine ensures sustainable innovation in order to develop a diversified and balanced pipeline of potentially first-in-class and/or best-in-class cutting-edge immunology and IO therapies, both independently, and through collaborations with global pharmaceutical and research institutions. Our HCAb and HBICETM platforms allow us to design unique and novel formats of antibodies, including bi- and multi-specific antibodies, that aim to exponentially enhance the clinical efficacy and safety of these candidates which are unachievable by combination therapies. We aspire to lead the next wave of immunotherapies in oncology and immunology.
Our portfolio also consists of strategically selected, in-licensed and risk-mitigated clinical assets with near-term revenue potential targeting diseases with high unmet need. Batoclimab (HBM9161) and tanfanercept (HBM9036) are the two anchor assets in this portfolio, and both of them are well positioned as the first mover to address significant unmet needs in their respective addressable markets in China.
The human tumor microenvironment is a unique bionetwork of heterogeneous collection of tumor cells along with different kind of immune cells, myeloid cells, lymphocytes, and a repertoire of signaling molecules. Approaches so far resulting into standard of care have met with limited success owing to several different factors including, but not limited to, access to the TME, heterogeneity of mechanisms involved with tumors, amongst others. Through rigorous biomarker analyses and artificial intelligence (machine learning) we aim to identify and establish the right immunotherapy for the right patient populations that would boost treatment outcomes. Targeting the immune cell engager pathways our HBICE approach is directed towards combining early and late stage immune engagers to prime and target the tumors for immediate and complete elimination. With a multi-pronged antibody (HBICE) approach to identify novel targets and mechanisms with in the TME, our goal is to transform cancer treatment paradigm by enabling the body’s own immune system to attack these tumors and bring long-term benefits to patients.
We focus on niche conditions with high unmet medical needs where a unique antibody approach combined with new or known targets may offer a meaningful therapeutic solution with a long-lasting impact for patients suffering from these conditions.
Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics
Utrecht University, Erasmus Medical Center and Harbour BioMed Researchers Report Discovery of Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells
Harbour BioMed Raises $75 Million Series B2 Venture Capital Financing to Accelerate Its Innovative Pipeline
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
Harbour BioMed Announces Completion of Phase 2 Study of HBM9036 in Patients with Moderate-to-Severe Dry Eye Disease in China
Yinuoke and Harbour BioMed Announce A Strategic Alliance to Develop Innovative Biologics to Address Unmet Patients' Needs
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics
Harbour BioMed integrates the Beacon® Platform to Accelerate Antibody Discovery
Harbour BioMed Receives Approval to Start the Phase II Clinical Trial of Its Innovative Drug Candidate for The Treatment of Inflammatory Eye Disease
Harbour BioMed Raises $85 Million in Series B Financing to Accelerate Its Innovative Pipeline
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Harbour BioMed Completes Series A3 Round Financing to Accelerate the Development of Clinical Programs and Company Growth
Harbour BioMed Established
Founder, Chairman and Chief Executive Officer
Mr. Jingsong Wang, M.D., Ph.D., is our principal Founder, Chairman and chief executive officer. Prior to founding our company, Dr. Wang served as head of China R&D and head of translational medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher ’s laboratory at the Harvard School of Public Health.
Chief Development Officer
Mr. Xiaoxiang Chen, M.D., is our chief development officer. Prior to Harbour BioMed, Mr. Chen served as Vice President of Medicine at Medicine and Regulatory department at Boehringer Ingelheim. Prior to that, Mr. Chen was Director of Clinical Research at Wyeth Asia Pacific R&D Center.
Chief Strategy Officer & Head, US Operations
Mr. Atul Deshpande, Ph.D., MBA, is our chief strategy officer and head of our U.S. operations. Prior to joining our Company, Dr. Deshpande served as Global Operations Lead of Sanofi Genzyme’s Dupixent® (dupilumab) franchise to launch its multi-billion and multi- indication products across the world. Prior to that he was the head of Asia Pacific R&D Strategy at Sanofi and also worked as a consultant for over 10 years across the full value chain of pharma.
Chief Commercial Officer
Mr. Mai-Jing Liao, Ph.D., MBA, is our Chief Commercial Officer. Prior to co-founding our company with Dr. Wang, Dr. Liao was at Xi’an Janssen Pharmaceutical Ltd. where he served in different roles with increasing responsibilities in Marketing, Strategic Marketing and Business Development.
Senior Vice President, Head of Technology Platform
Mr. Lile Liu, is our senior vice president, head of technology platform and head of Suzhou operations. Prior to joining our Company, Mr. Liu served as vice president of biologics discovery at ChemPartner. Prior to that, Mr. Liu served as operational vice president, antibody division, at GenScript.
Head of Discovery Biology
Mr. Yiping Rong, Ph.D., is our head of discovery biology. Prior to joining Harbour BioMed, Dr. Rong served as Associate Director of Cancer Research at Sanofi Asia Pacific R&D Center. Prior to that, Dr. Rong was the group leader of translational research in Janssen Discovery Center and the project leader of biologics discovery in Roche R&D.
Vice President, Head of Finance and Investor Relations
Helen is in charge of the overall financial strategy and management, corporate finance and investor relations. Prior to joining Harbour BioMed, she served as a Senior Audit Manager at EY. She has the dual qualifications of CPA (Certified Public Accountant) in China and US.
Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam
Founding Chief Scientific Officer, Harbour BioMed
Frank Grosveld, Ph.D., has served on our scientific advisory board since December 2016. Dr. Grosveld is the co-founder and CSO of Harbour Antibodies and the inventor of Harbour Mice®, a professor and former Head of the Department of Cell Biology and the Department of Clinical Genetics at the Erasmus University Medical Center, Rotterdam, a fellow of the Royal Society and a member of the Royal Netherlands Academy of Arts and Sciences. Dr. Grosveld’s research on the control of globin gene expression has been selected as one of the top ten achievements of Medical Research Council (UK) (MRC) in the 20th century by Higher Education and Research Opportunities in the U.K. Dr. Grosveld was awarded the Louis-Jeantet Prize for Medicine in 1991, the Spinozapremie (Spinoza Prize) in 1995.
Entrepreneur in Residence, Venture Partner at Third Rock Ventures, Independent non-Executive Director of HBM
Robert Kamen, Ph.D., has served on our scientific advisory board since 2016. Dr. Kamen is a Venture Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an independent non-executive Director of the Company and a director of Jounce Therapeutics (NASDAQ:JNCE). He was previously a director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was senior vice president of scientific affairs at the pioneering biotechnology firm named Genetics Institute, Inc.. Dr. Kamen received his bachelor ’s degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.
Eugene Opie First Centennial Professor of Pathology & Immunology, Washington University School of Medicine, Investigator, Howard Hughes Medical Institute, Member, US National Academy of Sciences
Kenneth Murphy, M.D., Ph.D., has served on our scientific advisory board since June 2019. Dr. Murphy is the Eugene Opie First Centennial Professor of Pathology & Immunology, Washington University School of Medicine in St. Louis, and a Member of the National Academy of Sciences. Dr. Murphy was awarded the William B. Coley Award for Distinguished Research in Basic Immunology by Cancer Research Institute in 2012 and the AAI-Thermo Fisher Meritorious Career Award by Thermo Fisher Scientific in 2016. Dr. Murphy received his bachelor degree in chemistry from Rice University and a Ph.D. in pharmacology and M.D. from Hopkins University School of Medicine.
Member of Chinese Academy of Engineering, Professor at University of Science and Technology of China (USTC), Director of Institute of Immunology of USTC, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science, and President of the school of Basic Medicine
Zhigang Tian, Ph.D., has served on our scientific advisory board since August 2020. Dr. Tian is a member of Chinese Academy of Engineering and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as a Director of Institute of Immunology, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science, and President of the school of Basic Medicine, and the former dean of School of Life Sciences of USTC. Dr. Tian was awarded with The National Science Fund for Distinguished Young Scholars. He is the academic leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.
Dr. Zhigang Tian’s laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK) cells, particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.
CSO of SalvaRx Therapeutics; BoD, Meditope Bioscience; Chair, NeoTx SAB; Member, Servier Pharma, Aro Biotherapeutics and Crown Biosciences SAB
Robert Kramer, Ph.D., has served on our scientific advisory board since December 2016. Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.
Chief CMC Advisor at Harbour BioMed, Former CEO, Adello Biologics
Peter Moesta, Ph.D., has served on our scientific advisory board since December 2016. He oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.
Chief Medical Officer at Cullinan Oncology, Advisor at PMP Capital
Jon Marc Wigginton, M.D., has served on our scientific advisory board since May 2020. Dr. Wigginton currently serves as Chief Medical Officer, Cullinan Oncology, and Advisor, MPM Capital. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease. Prior to MacroGenics, Dr. Wigginton served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic, translational and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer.
US$ 102.8 million
US$ 75 million
US$ 85 million
US$ 11.7 million